Mind Over Matter: BCI Tech Rewrites Chronic Stroke Recovery Rules

VAN NUYS, CA – August 18, 2026 – For decades, the conventional wisdom in neurology has been a somber one: after the first six months to a year following a stroke, the window for meaningful motor recovery largely closes. Patients with lingering weakness, particularly in the hand and arm, were often told their condition was chronic and permanent. Now, a groundbreaking study is providing the strongest evidence yet that this long-held belief is wrong, rewriting the rules of recovery with the power of thought.

Kandu, Inc., a California-based healthcare technology firm, has published the results of a landmark clinical trial for its IpsiHand® System, a non-invasive brain-computer interface (BCI) designed for at-home use. The study, published in the prestigious journal Stroke: Vascular and Interventional Neurology, confirms that the device can drive clinically significant improvements in hand function for patients, even many years after their stroke. The findings represent a major shift, moving advanced neuro-rehabilitation from the confines of a clinic into the patient's own living room and offering new hope where it was once scarce.

"Publication in this prestigious journal is exactly the kind of evidence that changes how a therapy is viewed and adopted," said Leo Petrossian, PhD, Chief Executive Officer of Kandu, Inc. "This most recent published clinical study adds to the already large body of evidence supporting the therapeutic benefit of IpsiHand as we build a new standard of care in non-invasive chronic stroke recovery."

A New Paradigm: The BCI-REHAB Study

The NIH-sponsored BCI-REHAB trial is the first randomized controlled study to evaluate an at-home, non-invasive BCI therapy for chronic stroke. Its results are nothing short of remarkable. The trial pitted the IpsiHand system against a standard home exercise program over 12 weeks. The IpsiHand device itself consists of a non-invasive EEG headset that reads the user's brainwaves and a sleek, wearable robotic handpiece.

Here’s how it works: A stroke often damages motor pathways on the side of the brain opposite the affected limb. However, the intention to move the hand still generates a detectable signal in the unaffected hemisphere (the ipsilateral side). The IpsiHand's headset detects this motor intent and, in near real time, wirelessly commands the handpiece to gently open or close the patient's impaired hand. This creates a feedback loop, reinforcing the neural connection between intent and action, and leveraging the brain's own capacity for change—a phenomenon known as neuroplasticity.

The results were so overwhelmingly positive that the trial was stopped early for efficacy. Patients using the IpsiHand system demonstrated an average improvement of 6.0 points on the Upper-Extremity Fugl-Meyer (UEFM) scale, a standard measure of motor function. This far surpassed the 1.5-point improvement seen in the control group and, critically, exceeded the 5.25-point threshold considered a Minimal Clinically Important Difference (MCID)—the smallest change that a patient would perceive as beneficial in their daily life.

More tellingly, 55.5% of IpsiHand users achieved this meaningful recovery, compared to just 9.6% in the control group. This translates to a Number Needed to Treat (NNT) of just 2.2, an exceptionally strong metric indicating that for every two to three patients treated with IpsiHand, one will achieve a clinically significant benefit they wouldn't have otherwise.

"This is the first randomized trial to show that engaging preserved ipsilateral neural signals through a noninvasive brain-computer interface can drive clinically meaningful motor recovery in chronic stroke," said Eric C. Leuthardt, MD, Chief Scientific Officer of Kandu and the study's principal investigator. "Patients and their families, who were told years ago that chronic stroke recovery was unlikely, now have further evidence that says otherwise."

From Clinic to Living Room: The Impact of At-Home BCI

Beyond the impressive statistics, the true impact of the IpsiHand system lies in its delivery model. By designing a safe, user-friendly device for at-home use, Kandu is dismantling one of the biggest barriers to long-term rehabilitation: access. The BCI-REHAB trial required no in-clinic appointments during the 12-week therapy period, empowering a diverse group of participants—ranging from 19 to 82 years old and from six months to over 30 years post-stroke—to take charge of their own recovery.

This at-home model addresses a critical need, particularly for those in rural or underserved communities where specialized rehabilitation centers are scarce. It also reduces the logistical and financial burden on patients and caregivers, allowing therapy to be integrated into daily life rather than dictating it. The study reported no serious or device-related adverse events, underscoring the safety of the non-invasive technology.

The potential for long-term use is also promising. While the trial measured outcomes at 12 weeks, the company notes that real-world evidence suggests patients may continue to improve with extended use, chipping away at deficits that were once thought to be permanent. For individuals who have spent years, or even decades, struggling with the simple tasks of dressing, eating, or holding a loved one's hand, this technology represents a tangible path toward regaining independence and quality of life.

Reshaping the Market for Stroke Recovery

The BCI-REHAB study is more than a scientific success; it's a strategic bombshell in the neuro-rehabilitation market. Armed with this robust clinical data, Kandu is poised to disrupt an industry that has long been starved for innovation in the chronic care space. The company's journey began in earnest when its IpsiHand system received FDA clearance in 2021 as a Breakthrough-Designated, de novo device—a classification reserved for novel technologies that provide for more effective treatment of life-threatening or irreversibly debilitating conditions.

That regulatory milestone opened the door, but this new peer-reviewed data provides the validation needed to build a highway. Robust evidence from a randomized controlled trial is the gold standard for convincing clinicians to adopt new therapies and, crucially, for persuading insurance companies to provide coverage. Widespread reimbursement is the final, critical step in making innovative technology accessible to the millions who need it.

While the neuro-tech landscape includes other promising technologies like robotics, functional electrical stimulation (FES), and virtual reality, IpsiHand's combination of being non-invasive, intent-driven, designed for home use, and now proven effective for the chronic stroke population, carves out a powerful and unique niche. It effectively expands the addressable market by offering a viable solution to a patient group previously sidelined.

Kandu's success signals a broader shift in healthcare, where technology is increasingly used to decentralize care, empower patients, and unlock the body's latent potential for healing. The BCI-REHAB study provides a compelling glimpse into a future where the brain's own signals can be harnessed to overcome physical limitations, proving that with the right technology, the line between chronic impairment and meaningful recovery is not as fixed as we once thought.